التفاصيل البيبلوغرافية
| العنوان: |
B cells as therapeutic targets in SLE. |
| المؤلفون: |
Sanz, Iñaki1 ignaciosanz@urrnc.rochester.edu, Lee, Eun-Hyung2, Sanz, Iñaki1 (AUTHOR), Lee, F Eun-Hyung (AUTHOR) |
| المصدر: |
Nature Reviews Rheumatology. Jun2010, Vol. 6 Issue 6, p326-338. 13p. 1 Diagram, 1 Chart, 3 Graphs. |
| مصطلحات موضوعية: |
*B cells, *TARGET organs (Anatomy), *SYSTEMIC lupus erythematosus, *AUTOIMMUNE diseases, *TUMOR necrosis factors, *RITUXIMAB, *CLINICAL trials, *BIOTHERAPY, *RESEARCH funding |
| مستخلص: |
The use of B-cell targeted therapies for the treatment of systemic lupus erythematosus (SLE) has generated great interest owing to the multiple pathogenic roles carried out by B cells in this disease. Strong support for targeting B cells is provided by genetic, immunological and clinical observations that place these cells at the center of SLE pathogenesis, as initiating, amplifying and effector cells. Interest in targeting B cells has also been fostered by the successful use of similar interventions to treat other autoimmune diseases such as rheumatoid arthritis, and by the initial promise shown by B-cell depletion to treat SLE in early studies. Although the initial high enthusiasm has been tempered by negative results from phase III trials of the B-cell-depleting agent rituximab in SLE, renewed vigor should be instilled in the field by the convergence of the latest results using agents that inhibit B-cell-activating factor (BAFF, also known as BLyS and tumor necrosis factor ligand superfamily, member 13b), further analysis of data from trials using rituximab and greatly improved understanding of B-cell biology. Combined, the available information identifies several new avenues for the therapeutic targeting of B cells in SLE. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
